[Drug exposure during pregnancy: a differentiated approach]
Related Experiment Video
Updated: Aug 23, 2026

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
1Swiss Teratogen Information Service (STIS), Division de pharmacologie et toxicologie cliniques, CHUV, Lausanne. philippe.rousso@chuv.hospvd.ch
Abstract:
Numerous drug exposures do occur unintentionally at the beginning of pregnancy. On the other hand, pursuing drug treatment may be necessary in women who wish to be pregnant. In these situations risk evaluation has to be done in a precise and differentiated manner, taking into account at the same time the risk for the fetus and maternal health. Teratovigilance services are able to give a thorough information enabling to avoid unwarranted drug arrests or pregnancy terminations. In return, physician's catamnesis about the outcome of the pregnancy exposed to one or several therapeutic agents will increase the bulk of knowledge health professionals and pregnant women have at their disposal.
Related Concept Videos
Factors Affecting Drug Response: Overview
Teratogenicity
Drug Toxicity: Risk factors
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
Drug Toxicity: Dose-Dependent Reactions
